Dr. Elysa Shaw, M.D.
Family Medicine (Family Medicine Physician)
13838 S 46th Pl Ste 125
Phoenix, AZ 85044
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
AZ license 35212
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 6 companies reported 13 payments worth $2,161 in total to this clinician.
| Amgen Inc. | $1,564 |
|---|---|
| Merck Sharp & Dohme LLC | $335 |
| Genentech USA, Inc. | $150 |
| Alnylam Pharmaceuticals Inc. | $56.66 |
| Genentech, Inc. | $32.21 |
| Novartis Pharmaceuticals Corporation | $23.57 |
| Travel and Lodging | $1,272 |
|---|---|
| Food and Beverage | $889 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $822 |
| Amgen Inc. Jul 23, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $375 |
| Merck Sharp & Dohme LLC Sep 25, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Phoenix, AZ Company’s descriptionProvided as part of a clinical research engagement. | $75.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 7 companies. The companies reported $116,023 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - Study name not reported
Eli Lilly and Company - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc. - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
Amgen Inc. - Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Eli Lilly and Company · Completed · NCT04627038 - A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company · Recruiting · NCT07285018 - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.